217691

CDC25 Phosphatase Inhibitor I, BN82002

The CDC25 Phosphatase Inhibitor I, BN82002, also referenced under CAS 396073-89-5, controls the biological activity of CDC25 Phosphatase. This small molecule/inhibitor is primarily used for Phosphorylation & Dephosphorylation applications.

• Synonyme(s) : CDC25 Phosphatase Inhibitor I, BN82002, N-(2-Hydroxy-3-methoxy-5-dimethylamino)benzyl, Nʹ-(2-(4-nitrophenethyl)), Nʹʹ-methylamine, PTP Inhibitor XX
• Formule empirique (notation de Hill): C₁₉H₂₅N₃O₄
• Numéro CAS: 396073-89-5
• Poids moléculaire : 359.42
• Code UNSPSC : 12352200
• Nomenclature NACRES : NA.77

Propriétés

• Niveau de qualité: 100
• Pureté: ≥95% (HPLC)
• Forme: solid
• Fabricant/nom de marque: Calbiochem^®
• Conditions de stockage: OK to freeze; protect from light
• Couleur: red to dark red
• Solubilité: DMSO: 10 mg/mL; ethanol: 10 mg/mL
• Conditions d'expédition: ambient
• Température de stockage: −20°C
• InChI: 1S/C19H25N3O4/c1-20(2)17-11-15(19(23)18(12-17)26-4)13-21(3)10-9-14-5-7-16(8-6-14)22(24)25/h5-8,11-12,23H,9-10,13H2,1-4H3
• Clé InChI: GOKYHQGRIIXMNE-UHFFFAOYSA-N

Description

Description générale

A cell-permeable ortho-hydroxybenzylamino compound that displays anti-tumor properties. Acts as a potent, selective, and irreversible inhibitor of CDC25 phosphatase family (IC₅₀ = 2.4, 3.9, 6.3, 5.4, and 4.6 µM for 25A, 25B2, 25B3, 25C, and 25C-cat, respectively). Displays ~20-fold greater selectivity for CDC25 phosphatases compared to CD45 tyrosine phosphatase. Shown to delay cell cycle progression in vitro (IC₅₀ in the range of 7.2-32.6 µM), and reduces tumor growth in athymic mice xenografted with the human pancreatic cell MIA PaCa-2 (15 mg/kg, i.p. route).

A cell-permeable ortho-hydroxybenzylamino compound that displays antitumor properties. Acts as a potent, selective and irreversible inhibitor of CDC25 phosphatase family (IC₅₀ = 2.4, 3.9, 6.3, 5.4, and 4.6 µM for 25A, 25B2, 25B3, 25C, and 25C-cat, respectively). Displays ~20-fold greater selectivity for CDC25 phosphatases over CD45 tyrosine phosphatase. Shown to delay cell cycle progression in vitro (IC₅₀ = ~7.2-32.6 µM), and reduces tumor growth in athymic mice xenografted with the human pancreatic cells MIA PaCa-2 (15 mg/kg, i.p. route).

Actions biochimiques/physiologiques

Cell permeable: yes

Primary Target
CDC25A

Product does not compete with ATP.

Reversible: no

Target IC₅₀: 2.4, 3.9, 6.3, 5.4, and 4.6 µM for CDC25 phosphatase family 25A, 25B2, 25B3, 25C, and 25C-cat, respectively

Conditionnement

Packaged under inert gas

Avertissement

Toxicity: Standard Handling (A)

Reconstitution

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C. Unstable in aqueous solution.

Autres remarques

Brezak, M.C., et al. 2004. Cancer Res.64, 3320.

Informations légales

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Informations sur la sécurité

• Code de la classe de stockage: 11 - Combustible Solids
• Classe de danger pour l'eau (WGK): WGK 1
• Point d'éclair (°F): Not applicable
• Point d'éclair (°C): Not applicable